SCM
ATXS

Stonepine Capital Management’s Astria Therapeutics ATXS Stock Holding History

Stonepine Capital Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-6,948
Closed -$182K – 32
2018
Q4 		$182K Sell
6,948
-29,155
-81% -$1.1M 0.16% 22
2018
Q3 		$1.73M Sell
36,103
-3,897
-10% -$175K 1.01% 24
2018
Q2 		$2.3M Buy
+40,000
New +$3.69M 1.4% 18

Other funds holding ATXS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return

Stonepine Capital Management's ATXS Position: Q1 2019 in Review

Stonepine Capital Management sold out of Astria Therapeutics (ATXS) in Q1 2019, closing a stake of 6,948 shares — an estimated $182K sold.

Stonepine Capital Management first reported a position in ATXS in Q2 2018 and held it in 3 quarters. The position peaked at $2.3M in Q2 2018. 28 funds tracked by Wall St. Rank hold ATXS as of Q1 2019.

  • Stonepine Capital Management reported no remaining Astria Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Stonepine Capital Management sold 6,948 Astria Therapeutics shares in Q1 2019, an estimated $182K.
  • Stonepine Capital Management first reported a position in Astria Therapeutics in Q2 2018 and held it in 3 quarters.
  • Stonepine Capital Management's Astria Therapeutics position peaked at $2.3M in Q2 2018.
  • 28 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2019.

Based on Stonepine Capital Management's 13F filing for Q1 2019, filed 14 May 2019.